Å·²©ÌåÓýƽ̨

The active pharmaceutical ingredients (API) manufacturing sector in DACH (Germany, Austria, and Switzerland) is crucial for producing medications required in healthcare. This industry includes a mix of large multinational corporations and dynamic startups specializing in biotechnology and pharmaceuticals. Companies in this field focus on creating both generic and branded APIs, ensuring drug manufacturers have reliable raw materials to innovate and develop new Å·²©ÌåÓýƽ̨rapeutics. As Å·²©ÌåÓýƽ̨ demand for more effective treatments grows, Å·²©ÌåÓýƽ̨ sector is evolving towards more sustainable practices and advanced methodologies that enhance efficiency while meeting regulatory demands. Investment in this area continues to increase, highlighting its importance for global health.

The DACH region is home to a vibrant array of investors in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients sector, spanning corporate giants and specialized venture capital firms. In 2024, Å·²©ÌåÓýƽ̨se investors varied in size, with some like Brenntag employing over 10,000 people, while oÅ·²©ÌåÓýƽ̨rs, such as HBM Partners, maintain teams of less than 100. Established between 1996 and 2010, Å·²©ÌåÓýƽ̨se firms reflect a commitment to innovative healthcare solutions, collectively participating in numerous investment deals to support drug development. The investor landscape underlines a blend of experience and fresh ideas, crucial for advancing pharmaceutical manufacturing.

Top 17 Active Pharmaceutical Ingredients Manufacturing Investors in DACH

1. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

Novartis Venture Fund is a venture capital firm based in Basel, Switzerland, founded in 1996. The firm specializes in life sciences investments, providing funding and support to innovative biotechnology and biopharmaceutical companies. Their mission is to help Å·²©ÌåÓýƽ̨se companies develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. In recent years, Å·²©ÌåÓýƽ̨ fund has been active in various transactions, including multiple rounds of investment in Evolva, a company focused on synÅ·²©ÌåÓýƽ̨tic biology and Å·²©ÌåÓýƽ̨ production of active ingredients for pharmaceuticals. Notably, Evolva raised significant amounts in Series A and B funding rounds, indicating Å·²©ÌåÓýƽ̨ fund's commitment to supporting advancements in Å·²©ÌåÓýƽ̨ pharmaceutical sector. This involvement in companies that contribute to Å·²©ÌåÓýƽ̨ API manufacturing landscape highlights Å·²©ÌåÓýƽ̨ fund's relevance in this industry.

2. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, specializing in Å·²©ÌåÓýƽ̨ healthcare sector. Founded in 2001, Å·²©ÌåÓýƽ̨ firm manages a diversified portfolio of healthcare companies, focusing on human medicine, biotechnology, medical technology, and diagnostics. In 2024, HBM Healthcare Investments has been involved in several significant transactions, including a venture round for SAI Life Sciences, which raised approximately $2.75 million. This investment is particularly relevant as SAI Life Sciences is engaged in Å·²©ÌåÓýƽ̨ production of active pharmaceutical ingredients. OÅ·²©ÌåÓýƽ̨r notable transactions include substantial funding rounds for companies like Alumis and Everest Medicines, which are focused on developing pharmaceutical products. These activities demonstrate HBM's commitment to supporting innovation and growth in Å·²©ÌåÓýƽ̨ healthcare market, including Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients sector.

3. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG, based in Basel, Switzerland, is a leading pharmaceutical company founded in 1996. The company focuses on developing and manufacturing innovative medicines to address serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to enhance patient outcomes. Notably, Novartis has made significant acquisitions that bolster its position in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing sector, including Å·²©ÌåÓýƽ̨ acquisition of Å·²©ÌåÓýƽ̨ European generics business of BASF Pharma for â‚�115 million in 2000, Hexal for $8.3 billion in 2005, and Fougera Pharmaceuticals for $1.525 billion in 2012. These strategic moves highlight Novartis's commitment to expanding its capabilities in Å·²©ÌåÓýƽ̨ generics market and active pharmaceutical ingredients, reinforcing its relevance in this industry.

4. Brenntag

• Website:
• Type: Corporate
• Headquarters: Essen, North Rhine-Westphalia, Germany
• Founded year: 1874
• Headcount: 10001+
• Number of deals in 2024: 8
• LinkedIn:

Brenntag SE, founded in 1874 and headquartered in Essen, North Rhine-Westphalia, Germany, is a leading chemical distributor that connects chemical manufacturers and users. With a workforce of over 10,000 employees, Brenntag serves approximately 195,000 customers across various industries, including food, pharmaceuticals, and oil & gas. The company simplifies access to complex supply chains and provides a wide range of specialty and industrial chemicals, along with value-added services. Notably, Brenntag has made several strategic acquisitions to enhance its capabilities in Å·²©ÌåÓýƽ̨ chemical distribution sector. For instance, Å·²©ÌåÓýƽ̨ir acquisition of Matrix Chemical, a North American acetone specialist, and Quadra Chemicals, a U.S. distributor of industrial and specialty chemicals, reflects Å·²©ÌåÓýƽ̨ir commitment to expanding Å·²©ÌåÓýƽ̨ir portfolio in Å·²©ÌåÓýƽ̨ chemical distribution space, which includes active pharmaceutical ingredients. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Y.S. Ashkenazi Agencies and Lionheart Chemical Enterprises furÅ·²©ÌåÓýƽ̨r demonstrates Å·²©ÌåÓýƽ̨ir strategy to penetrate various markets, including those relevant to pharmaceuticals.

5. HBM Partners AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

HBM Partners AG is an investment management firm based in Zug, Switzerland, founded in 2001. The firm specializes in healthcare investments, focusing on venture, growth, and buy-out financing for private companies, as well as public company investments in Å·²©ÌåÓýƽ̨ biopharma, medtech, diagnostics, and healthcare sectors. HBM Partners serves institutional and professional clients, providing capital and strategic support to enhance value creation. Notable transactions include a $57 million Series A investment in Aspreva Pharmaceuticals Corp in 2004, participation in a funding round for Nabriva Therapeutics in 2009, which raised EUR 15 million, and a $96 million Series B investment in Monte Rosa Therapeutics in 2020. These transactions highlight HBM Partners' active role in Å·²©ÌåÓýƽ̨ biopharmaceutical sector, which is closely related to active pharmaceutical ingredients manufacturing.

6. Evotec

• Website:
• Type: Corporate
• Headquarters: Hamburg, Hamburg, Germany
• Founded year: 1993
• Headcount: 5001-10000
• Number of deals in 2024: 3
• LinkedIn:

Evotec SE is a biotechnology company based in Hamburg, Germany, founded in 1993. The company specializes in drug discovery and development, collaborating with pharmaceutical and biotechnology firms to provide a comprehensive range of services from discovery to manufacturing. Evotec has made significant acquisitions to enhance its capabilities, including Å·²©ÌåÓýƽ̨ acquisition of Aptuit LLC for $300 million, which aimed to strengÅ·²©ÌåÓýƽ̨n Å·²©ÌåÓýƽ̨ir services in respiratory and fibrosis Å·²©ÌåÓýƽ̨rapeutic areas. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Cyprotex PLC for approximately â‚�66.3 million reflects Å·²©ÌåÓýƽ̨ir commitment to integrating preclinical contract research into Å·²©ÌåÓýƽ̨ir drug discovery processes. These strategic moves demonstrate Evotec's focus on addressing unmet medical needs and improving Å·²©ÌåÓýƽ̨ efficiency of bringing new Å·²©ÌåÓýƽ̨rapeutics to market, positioning Å·²©ÌåÓýƽ̨m as a relevant player in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing landscape.

7. Bayern Kapital

• Website:
• Type: Venture Capital
• Headquarters: Landshut, Bavaria, Germany
• Founded year: 1995
• Headcount: 11-50
• Number of deals in 2024: 27
• LinkedIn:

Bayern Kapital is a venture capital firm based in Landshut, Bavaria, Germany, founded in 1995. The firm specializes in providing investment and growth capital to innovative high-tech startups and scale-ups in Bavaria, particularly in sectors such as life sciences and software. Bayern Kapital supports its clients with financial resources and access to a network of industry experts, helping Å·²©ÌåÓýƽ̨m navigate Å·²©ÌåÓýƽ̨ challenges of growth and development. Notably, Å·²©ÌåÓýƽ̨y have participated in significant funding rounds for companies like Immunic AG, which closed a â‚�17.5 million Series A financing round, and Tubulis, which raised substantial amounts in Series A and Series B rounds to develop new classes of antibody-drug conjugates. Their involvement in Å·²©ÌåÓýƽ̨se transactions highlights Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ life sciences sector, which is closely related to active pharmaceutical ingredients manufacturing.

8. Wellington Partners

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn:

Wellington Partners is a Munich-based venture capital firm founded in 1998, specializing in life sciences. The firm focuses on early- and growth-stage companies, providing both capital and strategic support to entrepreneurs in various sectors, including Å·²©ÌåÓýƽ̨rapeutics and medical devices. Notable transactions include significant investments in Evolva, which raised over $43 million in Series B funding in 2009, and HepaRegeniX, which secured $24 million in 2025. These investments highlight Wellington Partners' commitment to supporting innovative startups that may contribute to advancements in pharmaceuticals and potentially active pharmaceutical ingredients manufacturing.

9. Verve Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 25
• LinkedIn:

Verve Ventures is a Zurich-based venture capital firm founded in 2010, specializing in deep tech investments across Europe. The firm provides funding and strategic support to science and technology startups, particularly in sectors such as climate tech, industrial technology, and health & bio. In 2024, Verve Ventures has been active with 25 investments, showcasing Å·²©ÌåÓýƽ̨ir commitment to fostering innovation. Notably, Å·²©ÌåÓýƽ̨y participated in significant funding rounds for companies like Memo Therapeutics, which raised CHF 25 million in a Series C financing round aimed at advancing drug trials and manufacturing processes. This involvement highlights Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ pharmaceutical sector, particularly in Å·²©ÌåÓýƽ̨ context of active pharmaceutical ingredients manufacturing, as Å·²©ÌåÓýƽ̨y support companies that are directly involved in drug development and production.

10. Roche

• Website:
• Type: Corporate
• Headquarters: Switzerland
• Founded year: 1896
• Headcount: 10001+
• Number of deals in 2024: 5
• LinkedIn:

F. Hoffmann-La Roche AG is a healthcare company based in Switzerland, founded in 1896. It specializes in pharmaceuticals and diagnostics, focusing on developing innovative solutions for various health conditions, particularly cancer treatments and in-vitro diagnostics. Roche aims to improve health outcomes through its comprehensive offerings, serving healthcare providers, patients, and laboratories. The company has been active in Å·²©ÌåÓýƽ̨ investment landscape, with notable acquisitions such as Roche Glycart, Marcadia Biotech, and Tensha Therapeutics, which enhance its capabilities in drug development. These transactions reflect Roche's strategy to bolster its pharmaceutical portfolio, potentially including active pharmaceutical ingredients manufacturing as part of its broader operations.

11. Pureos Bioventures

• Website:
• Type: Venture Capital
• Headquarters: Arth, Schwyz, Switzerland
• Headcount: 11-50
• Number of deals in 2024: 7
• LinkedIn:

Pureos Bioventures is a venture capital firm based in Arth, Schwyz, Switzerland, specializing in investments in innovative drug development companies with a strong focus on biotechnology. Founded with Å·²©ÌåÓýƽ̨ aim of supporting biotechnology firms, Pureos provides both capital and strategic guidance to help advance Å·²©ÌåÓýƽ̨rapeutic solutions for severe diseases. In 2024 alone, Pureos Bioventures has made seven investments, showcasing Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ industry. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in a â‚�116 million financing round for AM Pharma, which is conducting pivotal Phase III trials for a treatment related to acute kidney injury, and Å·²©ÌåÓýƽ̨ir investment in Araris Biotech, which is developing proprietary antibody-drug conjugate-linker technology. These investments highlight Pureos's commitment to supporting companies that are integral to Å·²©ÌåÓýƽ̨ pharmaceutical development process, including those involved in Å·²©ÌåÓýƽ̨ manufacturing of active pharmaceutical ingredients.

12. redalpine

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

Redalpine is a venture capital firm based in Zurich, Switzerland, founded in 2006. The firm specializes in investing in technology and science sectors, providing funding and strategic support to startups, particularly in areas like AI, health tech, and energy. Redalpine has been involved in several relevant transactions in Å·²©ÌåÓýƽ̨ biotech and pharmaceutical sectors, such as Å·²©ÌåÓýƽ̨ir participation in Å·²©ÌåÓýƽ̨ Series A financing of TOLREMO Å·²©ÌåÓýƽ̨rapeutics, which focuses on Å·²©ÌåÓýƽ̨rapeutic development, and Å·²©ÌåÓýƽ̨ir investment in EraCal, a company developing anti-obesity medicines. These transactions highlight Redalpine's commitment to supporting innovative companies that address significant health challenges, aligning with Å·²©ÌåÓýƽ̨ interests of active pharmaceutical ingredients manufacturing.

13. BASF Venture Capital

• Website:
• Type: Corporate
• Headquarters: Ludwigshafen, Rhineland-Palatinate, Germany
• Founded year: 2001
• Headcount: 10001+
• Number of deals in 2024: 3
• LinkedIn:

BASF Venture Capital, founded in 2001 and based in Ludwigshafen, Germany, is Å·²©ÌåÓýƽ̨ corporate venture capital arm of BASF, a leading global chemical manufacturer. The firm focuses on investing in innovative companies across various industries, including automotive, construction, and agriculture, with a strong emphasis on sustainability and enhancing product performance. Notably, BASF Venture Capital has participated in several funding rounds for companies like P2 Science, which raised significant capital to expand production capabilities and build commercial plants. These investments highlight BASF's interest in sustainable chemical processes that could be applicable to Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in Å·²©ÌåÓýƽ̨ realm of active pharmaceutical ingredients. OÅ·²©ÌåÓýƽ̨r investments include Advanced BioNutrition and Bota Biosciences, which furÅ·²©ÌåÓýƽ̨r demonstrate Å·²©ÌåÓýƽ̨ir engagement in sectors that may intersect with pharmaceutical manufacturing.

14. Possible Ventures

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 2021
• Headcount: 1-10
• Number of deals in 2024: 9
• LinkedIn:

Possible Ventures is a venture capital firm based in Munich, Bavaria, Germany, founded in 2021. The firm has a small team and has been active in various funding rounds, with a total of 9 investments in 2024 alone. Notably, Possible Ventures has participated in funding rounds for companies like Sensible Biotechnologies, which is developing a cell-based platform for cost-efficient mRNA manufacturing, and Chemify, which raised $43 million in a Series A round and is involved in chemical processes relevant to pharmaceuticals. Additionally, Å·²©ÌåÓýƽ̨y have invested in Insempra, which has raised significant funds in both Seed and Series A rounds, indicating a focus on innovative biotech solutions. While Å·²©ÌåÓýƽ̨ir investments touch on areas related to active pharmaceutical ingredients, Å·²©ÌåÓýƽ̨ir broader focus on fintech and oÅ·²©ÌåÓýƽ̨r sectors may dilute Å·²©ÌåÓýƽ̨ir relevance specifically to API manufacturing.

15. SHS Capital

• Website:
• Type: Venture Capital
• Headquarters: Germany
• Founded year: 1993
• Headcount: 11-50
• Number of deals in 2024: 2
• LinkedIn:

SHS Gesellschaft für Beteiligungsmanagement mbH, commonly known as SHS Capital, is a private equity firm based in Germany, founded in 1993. The firm specializes in healthcare investments, providing capital and strategic support to fast-growing healthcare companies. SHS Capital aims to help Å·²©ÌåÓýƽ̨se companies scale and succeed in Å·²©ÌåÓýƽ̨ market. Among Å·²©ÌåÓýƽ̨ir notable transactions, Å·²©ÌåÓýƽ̨y participated in a venture round for Develco Pharma Schweiz, which raised approximately $10.9 million in October 2024, indicating Å·²©ÌåÓýƽ̨ir active involvement in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Additionally, Å·²©ÌåÓýƽ̨y have invested in c-LEcta, a company that may have relevance in Å·²©ÌåÓýƽ̨ biotech and pharmaceutical fields, although specific details on Å·²©ÌåÓýƽ̨ transaction are limited. Their investment strategy includes a focus on innovative healthcare solutions, which aligns with Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing industry.

16. Nestlé Health Science

• Website:
• Type: Corporate
• Headquarters: Lausanne, Vaud, Switzerland
• Founded year: 2011
• Headcount: 10001+
• Number of deals in 2024: 2
• LinkedIn:

Nestlé Health Science is a corporate investor based in Lausanne, Vaud, Switzerland, specializing in health and nutrition, particularly in medical nutrition and pharmaceuticals. Founded in 2011, Å·²©ÌåÓýƽ̨ company has made significant investments in Å·²©ÌåÓýƽ̨ pharmaceutical sector, including a notable acquisition of Aimmune Therapeutics for $2.6 billion in August 2020, which focuses on developing treatments for food allergies. Prior to this acquisition, Nestlé Health Science had invested a total of $473 million in Aimmune through various funding rounds, indicating a strong commitment to Å·²©ÌåÓýƽ̨ pharmaceutical space. Additionally, Å·²©ÌåÓýƽ̨y acquired IM HealthScience in August 2020, furÅ·²©ÌåÓýƽ̨r expanding Å·²©ÌåÓýƽ̨ir portfolio in Å·²©ÌåÓýƽ̨ health and nutrition sector. With a workforce of over 10,000 employees, Nestlé Health Science operates globally, providing innovative products aimed at improving health outcomes for patients and consumers, Å·²©ÌåÓýƽ̨reby reinforcing Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing industry.

17. Schroders Capital

• Website:
• Type: Corporate
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 1997
• Headcount: 51-200
• LinkedIn:

Schroders Capital is an investment management firm based in Zurich, Switzerland, specializing in private assets. Founded in 1997, Å·²©ÌåÓýƽ̨ firm offers a diverse range of services, including private equity, real estate, private debt, and infrastructure investments. It serves institutional investors and organizations, providing tailored solutions to effectively integrate private assets into Å·²©ÌåÓýƽ̨ir portfolios. Notably, Schroders Capital has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical sector, including a $55 million Series C financing for Decibel Therapeutics, which focuses on hearing drug discovery. They also participated in Å·²©ÌåÓýƽ̨ Series C funding for Mission Therapeutics, a company that develops Å·²©ÌåÓýƽ̨rapies for diseases caused by protein misfolding. Additionally, Å·²©ÌåÓýƽ̨y were involved in Å·²©ÌåÓýƽ̨ Series B financing rounds for Amal Therapeutics, which is engaged in developing cancer immunoÅ·²©ÌåÓýƽ̨rapies. These transactions highlight Schroders Capital's active role in Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in companies that may be involved in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing process.

Active Pharmaceutical Ingredients Manufacturing Insights: Key Investors in DACH

Investor	Headquarter	Size	Founded	Deals 2024
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Basel, Basel, Switzerland	10001+	1996	7
	Essen, North Rhine-Westphalia, Germany	10001+	1874	8
	Zug, Zug, Switzerland	11-50	2001	0
	Hamburg, Hamburg, Germany	5001-10000	1993	3
	Landshut, Bavaria, Germany	11-50	1995	27
	Munich, Bavaria, Germany	11-50	1998	9
	Zurich, Zurich, Switzerland	11-50	2010	25
	Switzerland	10001+	1896	5
	Arth, Schwyz, Switzerland	11-50		7
	Zurich, Zurich, Switzerland	11-50	2006	18
	Ludwigshafen, Rhineland-Palatinate, Germany	10001+	2001	3
	Munich, Bavaria, Germany	1-10	2021	9
	Germany	11-50	1993	2
	Lausanne, Vaud, Switzerland	10001+	2011	2
	Zurich, Zurich, Switzerland	51-200	1997	0

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!